倪凌 - 清华大学

个人简介

倪凌，副研究员。2005年博士毕业于中科院微生物研究所；2006年在美国达拉斯贝勒免疫研究所开展博士后研究工作；2014年8月回国加入清华大学医学院董晨教授课题组。

研究领域

探究人体免疫学以及囊膜病毒感染和疫苗新机制

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Ling Ni#, Meng-Li Cheng#, Yu Feng#, Hui Zhao#, Jingyuan Liu, Fang Ye, Qing Ye, Gengzhen Zhu, Xiaoli Li, Pengzhi Wang, Jing Shao, Yong-Qiang Deng, Peng Wei, Fang Chen, Cheng-Feng Qin, Guoqing Wang, Fan Li*, Hui Zeng*, Chen Dong*. Impaired cellular immunity to SARS-CoV-2 in severe COVID-19 patients. Frontiers in immunology. 2020. Ling Ni#, Fang Ye#, Meng-Li Cheng#, Yu Feng, Yong-Qiang Deng, Hui Zhao, Peng Wei, Jiwan Ge, Mengting Gou, Xiaoli Li, Lin Sun, Tianshu Cao, Pengzhi Wang, Chao Zhou, Rongrong Zhang, Peng Liang, Han Guo, Xinquan Wang, Cheng-Feng*, Qin Fang Chen*, Chen Dong*. Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2. Immunity. 2020, 52, 971-977. Ling Ni, Yu Feng, Chen Dong*. The advancement of immunotherapy in HCC. Hepatoma Research. 2020. 6:25. Dongli Cai, Jiaming Li, Dingfeng Liu, Shanjuan Hong, Qin Qiao, Qinli Sun, Pingping Li, Nanan Lyu, Tiantian Sun, Shan Xie, Li Guo, Ling Ni*, Liping Jin*, Chen Dong*. Tumor-expressed B7-H3 mediates the inhibition of antitumorT-cell functions in ovarian cancer insensitive to PD-1blockade therapy. Cellular&molecular immunology. 2019. 17(3):227-236. Shanjuan Hong, Qing Yuan, Haizhui Xia, Genzhen Zhu, Yu Feng, Qiang Wang, Zhiyin Zhang, Wei He, Jian Lu*, Chen Dong*, Ling Ni*. Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy. Protein&cell. 2019.10(11):840-845. Shan Xie, Jia Huang, Qin Qiao, Wenjuan Zang, Shanjuan Hong, Haidong Tan, Chen Dong, Zhiying Yang*, Ling Ni*. Expression of inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunology, Immunotherapy. 2018, 67:1685-1694 Ling Ni* and Jian Lu*. Inferferon gamma in cancer immunotherapy. Cancer medicine. 2018; 7(9): 4509-4516 Ling Ni* and Chen Dong*. Roles of Myeloid and Lymphoid Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Frontiers in immunology. 2018; 9: 1-12. Ling Ni*. Comparison of PD-L1 and B7-H3 in cancer immunotherapy. Journal of immunology and immunotherapy. 2017; 1(1): 1-3 Ling Ni*. Non-redundant roles of new immune checkpoints in cancer evasion. Immunotherapy. 2017; 3(3):144-145 Ling Ni*, Chen Dong. New B7 family checkpoints in human cancers. Mol Cancer Ther. 2017; 16 (7): 1203-1211 Ling Ni*, Chen Dong*. New checkpoints in cancer immunotherapy. Immunological reviews. 2017; 276(1): 52- 65 Ling Ni, Ingrid Gayet, Sandra Zurawski, Dorothee Duluc, Anne-Laure Flamar, Xiao-Hua Li, Amy O’Bar, Anna Karolina Palucka, Gerard Zurawski, Jacques Banchereau, and SangKon Oh*. Concomitant activation and antigen uptake via human Dectin-1 results in potent antigen-specific CD8+ T cell responses. Journal of immunology. 2010, 185(6): 3504-13. Ling Ni, Linqing Zhao, Jieqing Zhu, Zhibo Jin, Po Tien* and George F. Gao*. Design and characterization of human respiratory syncytial virus entry inhibitors. Antiviral Therapy, 2005 (7): 833-40 Ling Ni, Jieqing Zhu, Junjie Zhang, Meng Yan, George F. Gao*, Po Tien*. Design of recombinant proteinbased SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain. Biochemical and Biophysical research communications, 2005 (330): 39-45. Ling Ni, Linqing Zhao, George F. Gao, Yuan Qian and Po Tien*. The antibodies directed against N-terminal heptad-repeat peptide of hRSV fusion protein and its analog-5-Helix inhibit virus infection in vitro. Biochemical and Biophysical research communications, 2005 (331): 1358-1364. Ling Ni, George F. Gao*，Po Tien*. Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics. Biochemical and Biophysical research communications, 2005(332): 831-836.